Activin-A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type-II Receptor Expression

5 May 2025

Benjamin J. DunmoreNobuhiro KikuchiWei LiPaul D. UptonNicholas W. Morrell

https://doi.org/10.1002/pul2.70095

Abstract

Activin-A is elevated in pulmonary arterial hypertension (PAH) patients, and reportedly suppresses BMPR-II. This suggests one mechanism of action for PAH drug, sotatercept, an activin-ligand trap. However, we were unable to confirm that activin-A reduces BMPR-II in pulmonary endothelial cells. Thus, it seems unlikely that sotatercept influences BMPR-II or PAH via this mechanism.

Read the full research letter

Share:
Additional comments are available to members. Login or register to become a member today